Drug treatment may benefit only select group of patients with glioblastoma
the ONA take:
Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas. They found that the drug does inhibit proteins that promote tumor growth; however, it also inhibits proteins that protect against cancer, a finding that negates any benefit of using the drug for patients with glioblastoma.
Findings from the researchers at Mayo Clinic, who conducted one of the clinical trials, suggest that pretesting glioblastoma biopsies may help identify those patients who will benefit from treatment with dasatinib. The drug is a general Src-family kinase (SFK) inhibitor.
The researchers teased apart the effect on individual Src family members (Src, Fyn, Yes, and Lyn). They found that dasatinib inhibited Src, Fyn, and Yes, which reduced growth and migration. It also inhibited Lyn, which protects against cancer growth.
The researchers also found that tumors express all members of the Src family differently, and expression of Yes and Lyn differed among tumors.
Although further testing is needed, the findings suggest that some patients may derive benefit from treatment with dasatinib, in particular those whose tumors express Yes, but not Lyn.
Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|